Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where K. Ueshima is active.

Publication


Featured researches published by K. Ueshima.


American Journal of Roentgenology | 2008

Radiofrequency ablation of hepatocellular carcinoma: value of virtual CT sonography with magnetic navigation.

Yasunori Minami; Hobyung Chung; Masatoshi Kudo; Satoshi Kitai; Shunsuke Takahashi; Tatsuo Inoue; K. Ueshima; Hitoshi Shiozaki

OBJECTIVE Virtual CT sonography with magnetic navigation yields cross-sectional images of CT volume data that correspond to the angle of the transducer in the magnetic field in real time. The purpose of this study was to evaluate the efficiency and feasibility of virtual CT sonography for radiofrequency ablation of hypervascular hepatocellular carcinoma poorly defined on B-mode sonography. MATERIALS AND METHODS One hundred one patients enrolled in the study were separated into two groups. Fifty-one patients with 65 hepatocellular carcinomas underwent prospective virtual CT sonography as guidance for radiofrequency ablation. Fifty patients with 63 hepatocellular carcinomas managed with B-mode sonographic guidance were retrospectively selected under the same conditions as the virtual CT sonography group to act as a historical control group. RESULTS In the virtual CT sonography group, technically successful ablation was achieved in a single session in 92% (47/51) of the patients and in two sessions in 8% (4/51). In the B-mode sonography group, technical success was achieved in a single session in 72% (36/50) of the patients, in two sessions in 24% (12/50), and in three sessions in 4% (2/50). Treatment analysis showed that the technical success rate after a single treatment session was significantly (p = 0.017) higher for the virtual CT sonography group. The number of treatment sessions was significantly (p = 0.021) lower for the virtual CT sonography group (mean, 1.1 +/- 0.1 vs 1.3 +/- 0.3 sessions). CONCLUSION Virtual CT sonographically assisted radiofrequency ablation is an efficient treatment of patients with hepatocellular carcinoma that is poorly defined on B-mode sonography.


British Journal of Cancer | 2012

Activation of JNK and high expression level of CD133 predict a poor response to sorafenib in hepatocellular carcinoma

Satoru Hagiwara; Masatoshi Kudo; Tomoyuki Nagai; Taisuke Inoue; K. Ueshima; Norifumi Nishida; Tsubasa Watanabe; Toshiharu Sakurai

Background:Hepatocellular carcinoma (HCC) ranks as the third leading cause of cancer deaths worldwide. While sorafenib, a multikinase inhibitor targeting the Raf/extracellular signal-regulated protein kinase (ERK) pathway, has been shown recently to provide a survival advantage to patients with advanced HCC, a predictive biomarker has not been developed. We studied whether c-Jun N-terminal kinase (JNK), which promotes liver carcinogenesis in mice, affects therapeutic response to sorafenib in HCC patients.Methods:We collected pathological specimens from 39 patients with advanced HCC before starting sorafenib treatment, and measured JNK activity in HCCs.Results:In patients treated with sorafenib, the expression of phospho-c-Jun in HCC, as a read out of JNK activity, was significantly higher (P<0.001) in the non-responder group than in the responder group. c-Jun N-terminal kinase activation in HCC was associated with a decreased time to progression and a poor overall survival (P=0.0028 and P=0.0008, respectively).Conclusion:In addition, JNK activity was significantly correlated with CD133 expression level. Correspondingly, high expression level of CD133 was linked to a poor response to sorafenib. Furthermore, D-JNKi, a specific JNK inhibitor, reduced the growth of xenografted CD133+ cells in athymic mice. In conclusion, JNK activation was positively correlated with CD133 expression level and inversely correlated with the therapeutic response to sorafenib, suggesting that JNK activity may be considered as a new predictive biomarker for response to sorafenib treatment.


Oncology | 2007

Percutaneous Radiofrequency Ablation of Sonographically Unidentifiable Liver Tumors

Yasunori Minami; Masatoshi Kudo; Hobyung Chung; Tatsuo Inoue; Shunsuke Takahashi; Kinuyo Hatanaka; Taisuke Ueda; Hitoshi Hagiwara; Satoshi Kitai; K. Ueshima; Toyokazu Fukunaga; Hitoshi Shiozaki

Objective: The purpose of this study was to evaluate the safety and feasibility of a real-time integrated system with computed tomography (CT) and sonographic images for radiofrequency (RF) ablation of hepatic malignancies poorly defined on B-mode sonography, and to clarify the suitable phase of CT images for using this virtual sonography. Methods: Between September 2004 and December 2004, 12 patients with 16 hepatocellular carcinomas and two metastatic lesions arising from colorectal adenocarcinoma (n = 1) and rectal carcinoid (n = 1) were treated. The maximum diameter of nodules ranged from 1.0 to 2.5 cm (mean ± SD; 1.5 ± 0.6 cm) on CT images. Results: Complete tumor necrosis was achieved in a single session in 19 lesions (90%), while a second session was required for the remaining two lesions (10%). Portal phase multi-planar reconstruction images were displayed under a suitable position corresponding to the ultrasound images in 9 patients (HCC = 7, metastasis = 2), and arterial phase multi-planar reconstruction images were displayed in the 3 remaining patients with hepatocellular carcinoma. Conclusion: Percutaneous RF ablation guidance using virtual sonography is an effective treatment for patients with hepatic malignancies. The portal phase of CT images may be the most suitable to indicate the 3-dimensional relationship between the liver vasculature and tumors on virtual sonography.


Journal of Hepatology | 2016

Prospective Randomized Controlled Phase III Trial Comparing the Efficacy of Sorafenib versus Sorafenib in Combination with Low-Dose Cisplatin/Fluorouracil Hepatic Arterial Infusion Chemotherapy in Patients with Advanced Hepatocellular Carcinoma

Masatoshi Kudo; K. Ueshima; Osamu Yokosuka; Shuntaro Obi; N. Izumi; Hiroaki Nagano; Etsuro Hatano; Yo Sasaki; Keisuke Hino; Takashi Kumada; Kyosuke Yamamoto; Yukinori Imai; Shouta Iwadou; Chikara Ogawa; Takuji Okusaka; Yasuyuki Arai; Fumihiko Kanai; Kohei Akazawa


Journal of Hepatology | 2017

Relationship between overall survival and time to progression after transarterial chemoembolization therapy in patients with hepatocellular carcinoma

Tadaaki Arizumi; K. Ueshima; Masatoshi Kudo


Journal of Hepatology | 2014

P551 EVALUATION OF ART SCORE FOR REPEATED TRANSARTERIAL CHEMOEMBOLIZATION IN JAPANESE COHORT OF HEPATOCELLULAR CARCINOMA

Tadaaki Arizumi; K. Ueshima; H. Chishina; M. Takita; S. Kitai; T. Inoue; N. Yada; S. Hagiwara; Y. Minami; T. Sakurai; N. Nishida; Masatoshi Kudo


Gan to kagaku ryoho. Cancer & chemotherapy | 2013

Recurrent hepatocellular carcinoma

K. Ueshima; Masatoshi Kudo


Nihon rinsho. Japanese journal of clinical medicine | 2012

Molecular targeted agent for hepatocellular carcinoma

K. Ueshima; Masatoshi Kudo


Journal of Hepatology | 2006

461 Carcinogenic risk factors in hepatitis B virus infection

S. Hagiwara; T. Nakatani; Y. Minami; Hobyung Chung; K. Ueshima; T. Fukunaga; Masatoshi Kudo; H. Munakata


Journal of Hepatology | 2006

248 Comparison of staging systems for hepatocellular carcinoma in a japanese cohort

Hobyung Chung; Masatoshi Kudo; S. Takahashi; T. Inoue; Y. Sakaguchi; S. Hagiwara; Y. Minami; K. Ueshima; T. Fukunaga; Takashi Matsunaga

Collaboration


Dive into the K. Ueshima's collaboration.

Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Top Co-Authors

Avatar
Researchain Logo
Decentralizing Knowledge